{"organizations": [], "uuid": "b4667b61e07fb11f5ee09f55aef9e1a9cb05ddfe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-immunovaccine-and-incyte-expand-cl/brief-immunovaccine-and-incyte-expand-clinical-collaboration-idUSFWN1S10NQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.21, "site_type": "news", "published": "2018-04-24T19:12:00.000+03:00", "replies_count": 0, "uuid": "b4667b61e07fb11f5ee09f55aef9e1a9cb05ddfe"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-immunovaccine-and-incyte-expand-cl/brief-immunovaccine-and-incyte-expand-clinical-collaboration-idUSFWN1S10NQ", "ord_in_thread": 0, "title": "BRIEF-Immunovaccine And Incyte Expand Clinical Collaboration", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "incyte", "sentiment": "negative"}, {"name": "immunovaccine inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Immunovaccine Inc:\n* IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER\n* IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTEâ€™S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE\n* IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL\n* IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-24T19:12:00.000+03:00", "crawled": "2018-04-25T14:32:11.000+03:00", "highlightTitle": ""}